B2BROKER
16.11.2023 13:11:30 CET | Business Wire | Press release
B2BinPay, the leading crypto payment processor, has once again raised the bar with its latest v18 solution update. Building upon the success of their previous v17 release, the company has introduced significant advancements for their clients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231116251906/en/
B2BinPay v18 update introduces Account Merge - Unifying Merchant and Enterprise Models and streamlining onboarding and business management processes. The update also comes with a fully renewed front-end and enhanced regulatory compliance. (Graphic: Business Wire)
The new release boasts a unified account system, merging the Merchant and Enterprise models and making transaction management easier than ever before. Coupled with a revamped front end and reinforced regulatory compliance, B2BinPay continues to prioritise UX and security in this latest version.
Let’s explore these cutting-edge updates further.
Account Unification
This update brings about a new philosophy in how B2BinPay delivers its services by unifying the two business models (Merchant and Enterprise) into one user-friendly interface.
What exactly does this mean for B2BinPay's clients? It means a more streamlined and integrated experience, as the platform combines both the Merchant and Enterprise account functionality into one user-friendly interface, which means clients can now manage all their transactions within a single, unified system.
But the benefits don't stop there. The account unification also simplifies the registration process, making it easier for businesses to join the platform and use its services immediately. With equal conditions and a single, unified onboarding fee for all types of users, clients have the freedom to choose and transition between services as their business needs evolve without the worry of extra costs or complex administrative processes. With this new approach, businesses can focus on what truly matters – their growth.
Revamped Front-End and Richer Functionality
The v18 release features a redesigned front end that not only aligns with the sleek aesthetic of the B2Broker brand but also offers improved speed and security for users. The core features that have made B2BinPay a favourite among its users have been maintained, ensuring a smooth transition to the updated platform. Here are the sections that have been completely redesigned:
- Wallets & Transfers
With a sleeker layout and optimised processes, users can quickly navigate through wallets & transfers sections without extra clicks and lengthy loadings. The update streamlines all financial operations, including payouts, bank withdrawals, and exchanges, providing a more seamless and time-saving experience for B2BinPay users.
- Account Menu
The renewed Account Menu features an intuitive, more user-friendly and secure design. Users can now easily manage their preferences, control API permissions, and customise their profile from one central location. Additionally, the 2FA feature adds an extra layer of security to protect user accounts from unauthorised access.
The Payment Page has also been revamped to reflect the updated design philosophy of B2Broker. This ensures that all financial transactions are carried out in a protected environment.
- Helpdesk
The updated Helpdesk provides a more streamlined and user-friendly experience for users. With a more defined schedule for multilingual support and new sticker notifications for incoming messages, users can now keep track of their inquiries more efficiently and receive timely responses from the B2BinPay team.
- Rates Interface
The Rates interface has undergone several upgrades. One of the major changes is that Rates now have richer filtering and favourites options. Additionally, the section can now be accessed directly from the top-level menu instead of being hidden in Wallets.
- Flexible Invoices
B2BinPay has removed the previous 7-day limit on merchant invoice expiration, allowing for customisation of timelines to fit each business's specific requirements better.
Complying with FATF Travel Rule
The v18 update brings enhanced Travel Rule compliance to the forefront. By partnering with Notabene, a leading provider of Travel Rule solutions, B2BinPay ensures strict adherence to the Financial Action Task Force (FATF) Travel Rules regulations.
The FATF Travel Rule requires VASPs, including B2BinPay, to collect and share personal information in cryptocurrency transactions to prevent money laundering and other unethical practices. New integration equipped B2BinPay with a robust system for detecting suspicious activities and eliminating fraud, providing clients with added peace of mind.
Final Remarks
In light of the growing popularity and acceptance of cryptocurrency, B2BinPay has established itself as a reliable and trustworthy solution in providing efficient crypto payment architecture for businesses. The launch of their v18 update showcases their commitment to constantly improving and expanding their services, staying ahead of market trends and regulatory standards.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116251906/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
